Oral health profile in patients infected with HTLV-1: Clinical findings, proviral load, and molecular analysis from HTLV-1 in saliva

Human T-lymphotropic virus type 1 (HTLV-1) is associated with adult T-cell leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and has also been implicated in several disorders, including periodontal disease. The proviral load is an important biological marker for understanding HTLV-1 pathogenesis and elucidating whether or not the virus is related to the clinical manifestation of the disease. This study describes the oral health profile of HTLV-1 carriers and HAM/TSP patients in order to investigate the association between the proviral load in saliva and the severity of the periodontal disease and to examine virus intra-host variations from peripheral blood mononuclear cells and saliva cells. It is a cross-sectional analytical study of 90 individuals carried out from November 2006 to May 2008. Of the patients, 60 were HTLV-1 positive and 30 were negative. Individuals from the HTLV-1 positive and negative groups had similar mean age and social-economic status. Data were analyzed using two available statistical software packages, STATA 8.0 and SPSS 11.0 to conduct frequency analysis. Differences of P?<?0.05 were considered statistically significant. HTLV-1 patients had poorer oral health status when compared to seronegative individuals. A weak positive correlation between blood and saliva proviral loads was observed. The mean values of proviral load in blood and saliva in patients with HAM/TSP was greater than those in HTLV-1 carriers. The HTLV-1 molecular analysis from PBMC and saliva specimens suggests that HTLV-1 in saliva is due to lymphocyte infiltration from peripheral blood. A direct relationship between the proviral load in saliva and oral manifestations was observed. J. Med. Virol. 84:1428-1436, 2012. (c) 2012 Wiley Periodicals, Inc.FAPESB [303/03]Brazilian Ministry of Health [306/04, 307/04

Mycobacterium tuberculosis epitope-specific interferon-g production in healthy Brazilians reactive and non-reactive to tuberculin skin test

The interferon (IFN)-gamma response to peptides can be a useful diagnostic marker of Mycobacterium tuberculosis (MTB) latent infection. We identified promiscuous and potentially protective CD4(+) T-cell epitopes from the most conserved regions of MTB antigenic proteins by scanning the MTB antigenic proteins GroEL2, phosphate-binding protein 1 precursor and 19 kDa antigen with the TEPITOPE algorithm. Seven peptide sequences predicted to bind to multiple human leukocyte antigen (HLA)-DR molecules were synthesised and tested with IFN-gamma enzyme-linked immunospot (ELISPOT) assays using peripheral blood mononuclear cells (PBMCs) from 16 Mantoux tuberculin skin test (TST)-positive and 16 TST-negative healthy donors. Eighty-eight percent of TST-positive donors responded to at least one of the peptides, compared to 25% of TST-negative donors. Each individual peptide induced IFN-gamma production by PBMCs from at least 31% of the TST-positive donors. the magnitude of the response against all peptides was 182 +/- 230 x 10(6) IFN-gamma spot forming cells (SFC) among TST-positive donors and 36 +/- 62 x 10(6) SFC among TST-negative donors (p = 0.007). the response to GroEL2 (463-477) was only observed in the TST-positive group. This combination of novel MTB CD4 T-cell epitopes should be tested in a larger cohort of individuals with latent tuberculosis (TB) to evaluate its potential to diagnose latent TB and it may be included in ELISPOT-based IFN-gamma assays to identify individuals with this condition.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Universidade Federal de São Paulo, Fac Med, Inst Coracao, Immunol Lab, São Paulo, BrazilUniversidade Federal de São Paulo, Fac Med, Dept Med, Div Imunol Clin & Alergia, São Paulo, BrazilFundacao Oswaldo Cruz, Lab Avancado Saude Publ, Salvador, BA, BrazilEscola Bahiana Med & Saude Publ, Salvador, BA, BrazilInst Invest Immunol, São Paulo, BrazilUniversidade Federal de São Paulo, Fac Med, Inst Coracao, Immunol Lab, São Paulo, BrazilUniversidade Federal de São Paulo, Fac Med, Dept Med, Div Imunol Clin & Alergia, São Paulo, BrazilWeb of Scienc

Evolution of HTLV-1 proviral load in patients from Salvador, Brazil

INTRODUCTION: Variations in human T cell lymphotropic virus type 1 (HTLV-1) proviral load (PVL) in infected individuals over time are not well understood. Objective: To evaluate the evolution of proviral load in asymptomatic individuals and HAM/TSP patients in order to help determine periodicity for measuring proviral load. METHODS: A group of 104 HTLV-1 infected patients, followed at the HTLV reference center in Salvador, Brazil, were included in the study (70 asymptomatic and 34 HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients). HTLV-1 PVL was measured using real-time polymerase chain reaction (PCR) at baseline and again at another point, either < 12 months, between 12-24 months, or > 24 months. RESULTS: HAM/TSP patients had higher PVL (ranging from 11,041 to 317,009 copies/10(6) PBMC) when compared to asymptomatic individuals (ranging from 0 to 68,228 copies/10(6) PBMC). No statistically significant differences were observed in the medians of PVL in HAM/TSP patients or asymptomatic individuals over time. However, in asymptomatic individuals with a PVL below 50,000 copies/10(6) PBMC, a statistically significant two-fold increase was observed over time. CONCLUSION: HTLV-1-PVL remained stable in both asymptomatic individuals and HAM/TSP patients over time. Frequent monitoring of asymptomatic individuals with low PVLs is recommended and further studies should be conducted to assess the course of PVL in these patients over extended periods of time

HTLV-1 proviral load as an indicative marker of HAM/TSP: a systematic review of studies of patients with HAM/TSP

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2018-04-17T13:05:21Z No. of bitstreams: 1 Bassi SS HTLV-1 proviral load as an indicative marker of HAM....pdf: 167971 bytes, checksum: af9c0fc5308d4415d1a3823ef36e65cd (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2018-04-17T13:23:31Z (GMT) No. of bitstreams: 1 Bassi SS HTLV-1 proviral load as an indicative marker of HAM....pdf: 167971 bytes, checksum: af9c0fc5308d4415d1a3823ef36e65cd (MD5)Made available in DSpace on 2018-04-17T13:23:31Z (GMT). No. of bitstreams: 1 Bassi SS HTLV-1 proviral load as an indicative marker of HAM....pdf: 167971 bytes, checksum: af9c0fc5308d4415d1a3823ef36e65cd (MD5) Previous issue date: 2014Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / University of York. Centre for Immunology and Infection. Department of Biology. Biology Graduate. New York, UKFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, BrasilEscola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilUniversity of York. Hull and York Medical School. Centre for Immunology and Infection. Department of Biology. New York, UKFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilThe diagnosis of HAM/TSP is based on criteria, as proposed by the World Health Organization, revised in 1989. This primarily relies on diagnosis through laboratory criteria and an extensive list of neurological signs and symptoms. Consequentially HAM/TSP diagnosis is often delayed or not confirmed, especially in countries with limited resources

Giant disseminated condylomatosis in SLE

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2014-10-06T13:47:19Z No. of bitstreams: 1 Pinto LC Giant....pdf: 155752 bytes, checksum: 15238154902b5390cef26e59d054fb41 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2014-10-06T13:47:35Z (GMT) No. of bitstreams: 1 Pinto LC Giant....pdf: 155752 bytes, checksum: 15238154902b5390cef26e59d054fb41 (MD5)Made available in DSpace on 2014-10-06T14:03:55Z (GMT). No. of bitstreams: 1 Pinto LC Giant....pdf: 155752 bytes, checksum: 15238154902b5390cef26e59d054fb41 (MD5) Previous issue date: 2012Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Universidade Federal da Bahia. Departamento de Ginecologia e Obstetrícia. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilLaboratório Silvany Studart. Salvador, BA, BrasilUniversidade Federal da Bahia. Departamento de Ginecologia e Obstetrícia. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilEscola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilIntroduction: Females with systemic lupus erythematosus (SLE) have higher prevalence of human papillomavirus (HPV) infection, which can lead to the development of warts. Herein we report the first case of giant disseminated condylomatosis (GDC) in a SLE female on mycophenolate mofetil (MMF). Case report: The patient, a 33-year-old, Black female, was diagnosed with SLE during her first pregnancy in 2003 based on the features of arthritis, skin rash, seizures, nephritis and presence of antinuclear antibodies. Her pregnancy resulted in preterm delivery of a stillborn fetus at 28 weeks. Since that time she has been treated with steroids and different regimens of immunosuppressive drugs such as cyclophosphamide, azathioprine and lately MMF. In the last few years she presented GDC involving the genital area in addition to skin on the lower abdomen. Topical therapy with trichloroacetic acid, imiquimod and podophyllin was only partially effective. Different types of HPV were identified in the lesions, being HPV-11 in abdomen, HPV 6, 11, 42 in vulva, HPV-6, 11 in vagina and HPV-6, 11 in endocervix. Conclusions: GDC may be a complication of SLE, secondary to the disease itself, its treatment or other factors not yet identified

Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers.

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2014-09-26T13:06:19Z No. of bitstreams: 1 Coutinho JR R Human T lymphotropic....pdf: 379342 bytes, checksum: 969d067a806ee69ee55498bac2a518a0 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2014-09-26T13:06:35Z (GMT) No. of bitstreams: 1 Coutinho JR R Human T lymphotropic....pdf: 379342 bytes, checksum: 969d067a806ee69ee55498bac2a518a0 (MD5)Made available in DSpace on 2014-09-26T13:27:12Z (GMT). No. of bitstreams: 1 Coutinho JR R Human T lymphotropic....pdf: 379342 bytes, checksum: 969d067a806ee69ee55498bac2a518a0 (MD5) Previous issue date: 2014Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Bahiana School of Medicine and Public Health. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, BrasilBahiana School of Medicine and Public Health. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Bahiana School of Medicine and Public Health. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Bahiana School of Medicine and Public Health. Salvador, BA, BrasilBackground: High HTLV-1 proviral load (PVL) is mainly found in infected individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However one third of asymptomatic carriers may have high PVL. This study aimed to evaluate the impact of PVL in the activation of T lymphocytes of asymptomatic individuals infected with HTLV-1. Methods: Membrane activation markers (CD25+, CD28+, CD45RO+, CD69+, CD62L+, HLA-DR+), FoxP3+ and intracellular IFN-γ expression were evaluated on both CD4+ and CD8+ T-lymphocytes from asymptomatic carriers with PVL ≥ and < 1% of infected cells, using flow cytometry. HTLV-1 proviral load was determined using real-time PCR. Results: Asymptomatic carriers with PVL ≥ 1% presented a higher frequency of CD4+CD25+CD45RO+ (13.2% vs. 4%, p = 0.02), CD4+HLA-DR+ (18% vs. 8.3%, p = 0.01) and CD4+IFN-γ+ (4.5%; 1%, p = 0.01) T-cells, than healthy donors. HTLV-1 PVL was directly correlated with the proportion of CD4+CD25+CD45RO+ T-cells (R = 0.7, p = 0.003). Moreover, a significant increase in the proportion of CD4 + FoxP3+ T-cells was observed in HTLV-1-infected individuals, compared to healthy donors. Conclusion: HTLV-1 PVL is associated with activation of both CD4+ and CD8+ T-lymphocytes in asymptomatic individuals. Prospective studies should be conducted to evaluate whether asymptomatic individuals with higher PVL and high immune activation are more prone to developing HTLV-1-associated disease

Utility of HTLV proviral load quantification in diagnosis of HTLV-1-associated myelopathy requires international standardization

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2014-07-07T18:50:34Z No. of bitstreams: 1 Grassi MFR Utility of HTLV....pdf: 384010 bytes, checksum: 72b8bc25c145a7bffb020966102c828e (MD5)Made available in DSpace on 2014-07-07T18:50:34Z (GMT). No. of bitstreams: 1 Grassi MFR Utility of HTLV....pdf: 384010 bytes, checksum: 72b8bc25c145a7bffb020966102c828e (MD5) Previous issue date: 2013Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Advanced Laboratory of Public Health. Salvador, BA, Brasil / Bahiana School of Medicine and Public Health (EBMSP). Salvador, BA, BrasilBahiana School of Medicine and Public Health (EBMSP). Salvador, BA, BrasilBahiana School of Medicine and Public Health (EBMSP). Salvador, BA, BrasilSt. Marianna University School of Medicine. Institute of Medical Science. Department of Rare Diseases Research. Kanagawa, JapanViral Immunology Section. NINDS/NIH. Bethesda, MD, USAImperial College London. Faculty of Medicine,. Section of Infectious Diseases. London, United KingdomUniversity of York. Centre for Immunology and Infection. Department of Biology. Hull and York Medical School. York, United KingdomFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Advanced Laboratory of Public Health. Salvador, BA, Brasil / Bahiana School of Medicine and Public Health (EBMSP). Salvador, BA, Brasi